Please login to the form below

Not currently logged in
Email:
Password:

Chinese pharma industry output to reach USD 79bn in 2007

According to a report released by the Chinese State Food and Drug Administration's Southern Medicine Economic Research Institute (SMERI), total gross industrial output value of China's pharmaceutical industry may reach CNY 600bn (USD 79bn) in 2007, up 17.8 per cent to 18.5 per cent compared with 2006 figures.

According to a report released by the Chinese State Food and Drug Administration's Southern Medicine Economic Research Institute (SMERI), total gross industrial output value of China's pharmaceutical industry may reach CNY 600bn (USD 79bn) in 2007, up 17.8 per cent to 18.5 per cent compared with 2006 figures.

The Chinese government launched a series of polices to increase regulation in the pharmaceutical industry in May 2007, with some small or unregulated companies excluded from the market or completely shut down.

In 2006, the top 100 domestic pharmaceutical manufacturers brought in 30 per cent of total sales, while those generated by the top 100 pharmaceutical distributors accounted for 67.9 per cent of the total.

The SMERI report said that, although the pharmaceutical industry in China is still highly segmented, a trend towards additional consolidation in the near future is now identifiable.

According to the China Association of Pharmaceutical Commerce, H1 2007 sales from seven categories of pharmaceutical products reached CNY 127.4bn (USD 16.8bn), or a year-on-year growth rate of 9.6 per cent. SMERI said that this growth will be maintained in H2 2007.

After three rounds of price cut policies instituted in January 2007, SMERI said there would be no further significant adjustments to drug prices. The National Development and Reform Commission will now adjust the prices of drugs on the basic medical insurance list once every two years and will also continue to increase the number of drugs listed on the basic medical insurance list.

Chinese counterfeit malaria drugs recalled from Africa
According to government reports, Chinese pharmaceutical company Holley-Cotec has said it will recall thousands of anti-malarial drugs supplied in Kenya after the government there uncovered a counterfeit syndicate.

An analysis conducted by the Malaria Control Unit in Kenya found that the drug artemisinin had low levels of active ingredients leaving patients taking the drug without protection.

MCU spokesperson Willy Akwale told a press conference that the drug was produced by Holley-Cotec Pharmaceuticals headquartered in China, with up to 20,000 doses for sale on the Kenyan market.

The Kenyan ministry of health has intensified campaigns to crack down on counterfeit drugs readily available in the country.

21st August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...